Related Experiment Video
Updated: Sep 27, 2026
13:17
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion
1Wistar Institute, 3600 Spruce Street, Philadelphia, PA 19104, USA. ertl@wistar.upenn.edu
Current Opinion in Molecular Therapeutics
|February 25, 2003
Abstract:
Therion Biologics, in collaboration with Aventis Pasteur, is developing ALVAC-CEA/B7.1, a recombinant, pox virus-based vaccine that targets carcinoembryonic antigen (CEA) found on the surface of lung and colorectal tumor cells, for the potential treatment of lung and colorectal cancer. The vaccine is in phase II clinical trials for these indications.
